Instead of passively investing, Forty51 Ventures actively builds its portfolio companies. They serve as the first capital in, often in-licensing IP or building it from scratch, then recruiting the team and writing the development plans. This operational model is designed to manufacture investable opportunities from the ground up.

Unlike many American competitors, Roche's identity as a company from a small country (Switzerland) forces a global perspective from day one. Their strategy and clinical trials are designed for worldwide applicability, engaging with diverse markets like China and Latin America directly.

Instead of passively waiting for pitches, proactive VCs like Foresight Capital build new companies by acquiring promising assets. They actively source clinical or later-stage assets, particularly from Asia where market dynamics are favorable, and then build a new company around them with a proven entrepreneur from their network.

Venture capital firm Sofinnova prioritizes hiring experienced pharma operators, even those with zero investment background. These experts provide invaluable hands-on guidance on drug development and commercialization to portfolio companies, contributing to a high rate of FDA product approvals.

Complement Therapeutics intentionally built a presence across the UK, Germany, and the US to optimize talent acquisition. This cross-geographical structure allows them to hire the best experts in a specialized field like gene therapy, irrespective of their location, without being constrained by a single talent pool or dealing with complex relocations.

The successful 'NewCo' model, initially focused on in-licensing assets from Asia for Western development, is evolving. Companies like Boulevard Bio now create hybrid entities that combine assets from Asia with those from the U.S. or other global sources, diversifying their pipelines and de-risking their geographic concentration from inception.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

Beyond a supportive ecosystem, CDR Life's CEO highlights Switzerland's dense concentration of well-trained life science professionals from big pharma, biotech, and top universities as its most critical advantage. This makes it easier to hire and retain the specialized talent essential for a biotech's success.

Basel, with fewer than 200,000 residents, thrives as a global biotech hub by drawing talent from neighboring France and Germany. Its key advantage is serving as a nexus for navigating Europe's complex, country-specific regulatory landscapes, making it an attractive base for life science companies.